The object of the study is to determine whether different doses of SCH 530348, when added to standard medical care in persons undergoing percutaneous coronary intervention, will increase the risk of bleeding. A secondary objective is to determine whether patients treated with SCH 530348 have fewer cardiac events such as heart attack, bypass surgery, or death compared with those persons treated with the standard of care.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
1,030
Incidence of bleeding through the end of treatment in subjects undergoing percutaneous coronary intervention
Incidence of bleeding throughout treatment and follow-up
Incidence of death and major adverse cardiac events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.